Sugi Predict

Sugi Predict / Compounds / SCHEMBL1980208

SCHEMBL1980208

SCHEMBL1980208

COc1cccc(Oc2ccc(N3C(=O)N[C@H](C)C3=O)cc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.52
▸ MAPT P10636 3/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ HTT P42858 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.51
▸ NTRK1 P04629 1/20 0.47
▸ IGF1R P08069 1/20 0.47
▸ FGFR1 P11362 1/20 0.47
▸ NTRK2 Q16620 1/20 0.47
▸ MMP13 P45452 1/20 0.46
▸ MTNR1B P49286 4/20 0.43
▸ MTNR1A P48039 3/20 0.43
▸ MGLL Q99685 2/20 0.42
▸ HSD17B10 Q99714 1/20 0.41
▸ KDM4C Q9H3R0 1/20 0.41
▸ BRD4 O60885 1/20 0.41
▸ AADAT Q8N5Z0 1/20 0.41
▸ ABCB1 P08183 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30939557 1.00 LMNA (0.52) LMNAMAPTSMN1; SMN2ALDH1A1HTT
SCHEMBL1979602 0.87 LMNA (0.52) LMNAMAPTALDH1A1HTTMMP13
SCHEMBL30939548 0.87 LMNA (0.52) LMNAMAPTALDH1A1HTTMMP13
SCHEMBL1979600 0.86 LMNA (0.49) LMNAMAPTSMN1; SMN2ALDH1A1HTT
SCHEMBL13879468 0.86 MGLL (0.57) LMNAMAPTSMN1; SMN2ALDH1A1HTT
SCHEMBL8726554 0.84 MGLL (0.53) LMNAMAPTALDH1A1RAB9AMGLL
SCHEMBL17354611 0.84 LMNA (0.55) LMNAMAPTSMN1; SMN2ALDH1A1HTT
SCHEMBL30939514 0.84 LMNA (0.49) LMNAMAPTSMN1; SMN2ALDH1A1HTT
SCHEMBL1982043 0.84 LMNA (0.49) LMNAMAPTSMN1; SMN2ALDH1A1HTT
SCHEMBL1978190 0.83 LMNA (0.45) LMNAMAPTSMN1; SMN2ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 — — US claimed
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-11-29 — — US claimed
US-10058551-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2018-08-28 — — US claimed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 — — US claimed
US-9849131-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2017-12-26 — — US claimed
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2017-03-09 — — US claimed
EP-2509961-B1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LTD (GB) 2016-03-09 — — EP claimed
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2016-03-03 — — US claimed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 — — US claimed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US claimed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 — — EP claimed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 — — WO claimed
US-20250017925-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN AUTIFONY THERAPEUTICS LIMITED (GB) 2025-01-16 — — US disclosed
CN-118267386-A Modulators of KV3 channels for the treatment of pain 奥提芙尼治疗学有限公司 2024-07-02 — — CN disclosed
CN-108472288-B Modulators of KV3 channels for the treatment of pain 奥提芙尼治疗学有限公司 2024-05-28 — — CN disclosed
US-11944623-B2 Modulators of Kv3 channels to treat pain AUTIFONY THERAPEUTICS LIMITED (GB) 2024-04-02 — — US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US disclosed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 — — EP disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 — — WO disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 LMNA 2187/4885MAPT 3762/4885SMN1; SMN2 2526/4885
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 LMNA 2187/4885MAPT 3762/4885SMN1; SMN2 2526/4885
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 LMNA 2187/4885MAPT 3762/4885SMN1; SMN2 2526/4885
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 LMNA 2187/4885MAPT 3762/4885SMN1; SMN2 2526/4885
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 LMNA 2187/4885MAPT 3762/4885SMN1; SMN2 2526/4885
US-10058551-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 LMNA 2187/4885MAPT 3762/4885SMN1; SMN2 2526/4885
US-11944623-B2 Modulators of Kv3 channels to treat pain KCNN3, KCNA3, KCND3 LMNA 2943/4885MAPT 2780/4885SMN1; SMN2 2182/4885
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 LMNA 2517/4885MAPT 3789/4885SMN1; SMN2 2949/4885
US-20250017925-A1 MODULATORS OF KV3 CHANNELS TO TREAT PAIN KCNN3, KCNA3, KCND3 LMNA 2943/4885MAPT 2780/4885SMN1; SMN2 2182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.